Arvinas stock downgraded by BofA as Pfizer partnership shifts
NegativeFinancial Markets

Arvinas has faced a setback as Bank of America downgraded its stock following a shift in its partnership with Pfizer. This change raises concerns about the future of their collaboration and could impact investor confidence. The downgrade reflects broader market sentiments and highlights the challenges biotech companies face in maintaining strong partnerships.
— Curated by the World Pulse Now AI Editorial System